2022 Fiscal Year Final Research Report
Novel treatment innovation for xerostomia applying anti-VEGF antibody
| Project/Area Number |
20K18609
|
|---|
| Research Category |
Grant-in-Aid for Early-Career Scientists
|
| Allocation Type | Multi-year Fund |
|---|
| Review Section |
Basic Section 57050:Prosthodontics-related
|
|---|
| Research Institution | Kyushu Dental College |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2020-04-01 – 2023-03-31
|
| Keywords | 唾液 / 唾液腺 / VEGF / 抗VEGF抗体 / 糖尿病 / 口腔乾燥症 / 炎症 / AQP5 |
|---|
| Outline of Final Research Achievements |
Xerostomia, a common symptom of diabetes, often causes various problems in dental prosthetic treatment. This study aims to evaluate the efficacy of applying ranibizumab (RBZ), the anti-vascular endothelial growth factor (anti-VEGF) antibody, for restoring salivary function in KK-Ay mice, a type 2 diabetes model. As a result of the submandibular gland perfusion experiment, saliva secretion in RBZ administrated group significantly increased compared to the non-administrated group. Moreover, immunohistochemistry revealed that the localization of Aquapolin 5, which plays an important role in fluid secretion, was changed under the influence of RBZ administration. Therefore, it was suggested that applying an anti-VEGF antibody may improve the symptoms of xerostomia in diabetic patients.
|
| Free Research Field |
唾液生理学
|
| Academic Significance and Societal Importance of the Research Achievements |
糖尿病に合併する口腔乾燥症は、唾液分泌量の低下によりインプラント周囲炎や歯周病の増悪、義歯の維持困難などを引き起こし、歯科補綴治療に際し問題となることも少なくない。本研究では、抗VEGF抗体ラニビズマブ（RBZ）を糖尿病モデルマウスに応用した結果、唾液分泌量が有意に増加することが明らかとなった。そのメカニズムはまだ明らかではないが、水分泌に関与するAquapolin 5の発現位置がRBZ投与群で異なることが一因となっている可能性がある。今後、唾液分泌量がRBZの応用により回復するメカニズムについての詳細が解明できれば、糖尿病患者における口腔乾燥症治療法確立の一助となることが期待される。
|
